KYOTO-SEMICONDUCTOR
26.5.2020 07:02:11 CEST | Business Wire | Press release
In the forty years since the company’s founding, Kyoto Semiconductor Co., Ltd., Tsuneo Takahashi, President and CEO, and headquartered in Fushimi Ward, Kyoto, has led the industry with optical solutions built from world-standard technologies and with Japanese quality and attention to production detail. They have announced the development of a Two-Wavelength Photodiode, the KP-2 Two-tone Photodiode KPMC29, in the industry’s smallest class and capable of being surface-mounted, with silicon and indium-gallium-arsenide photodiodes, with photosensitivity for a wide range of wavelengths, from 400 to 1,700 nm, arrayed along the same light axis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005017/en/
This broadband sensitivity, together with a smaller package that is 1/8 the volume ratio of older Kyoto Semiconductor products, can be used in the healthcare field for applications that include medical biometric monitoring like pulse oximeters as well as wearable activity monitors. Because it is also possible to independently produce photocurrent signals from the silicon and indium-gallium-arsenide photodiodes, measuring the photocurrent ratio will allow for its use as a radiation thermometer that can measure temperatures without direct contact with hot object.
Development Background
Spectroscopic analysis technology, that allows for the identification of objects and their characteristics without needing direct contact with those objects, by reflecting light of those objects and measuring the degrees of transmission and reflection, is increasingly needed in a wide range of fields, including medicine, production, and security. Spectroscopic analysis relies on two factors for successful use in identifying a wide range of objects: a wider range of wavelengths, or colors, for the source wavelengths, and a wider range of sensitivity for those wavelengths with the photodiode end. There is also a need for smaller products, compared to existing corded-lead products, for use with medical equipment or wearable devices that can be worn directly on the human body.
Development was therefore undertaken to meet these product needs.
Product Characteristics
-
A wider range of wavelength sensitivity (400~1,700nm).
To expand the wavelength range, we layered both silicon photodiodes, which are sensitive to shorter wavelengths, and indium-gallium-arsenide photodiodes, which are sensitive to longer wavelengths, along the same light axis. -
A compact surface-mountable package in the industry’s smallest class.
To successfully make this KP-2 two-tone PD smaller, the indium-gallium-arsenide photodiodes were laid down in pits arranged on the base for the silicon photodiodes, which ordinarily allows light to pass through. This allowed for the package height to be as low as possible. (Patents have been filed.)
Compared to earlier products from Kyoto Semiconductor, the volume ratio has been reduced to 1/8.
See the following for more information. (https://www.kyosemi.co.jp/en/lp/kpmc29/ )
Samples will be available from August 31, 2020.
Mass production orders will begin on April 1, 2021.
Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
Company Website: https://www.kyosemi.co.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200525005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Commits $49bn to Local Manufacturers7.5.2026 16:00:00 CEST | Press release
UAE to localize 5,000+ products in push for industrial sovereignty – Minister of Industry and Advanced Technology and ADNOC Group CEO Dr. Sultan Al Jaber The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical producti
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
